is predicted to increase the exposure to eletriptan.

Study

▶ Cobicistat is predicted to markedly increase the exposure to

eletriptan. Avoid.rStudy

▶ Eletriptan increases the risk of vasoconstriction when given

Study

with ergotamine. Separate administration by 24 hours.r

▶ HIV-protease inhibitors are predicted to markedly increase the

exposure to eletriptan. Avoid.rStudy

▶ Idelalisib is predicted to markedly increase the exposure to

eletriptan. Avoid.rStudy

▶ Macrolides (clarithromycin) are predicted to markedly increase

the exposure to eletriptan. Avoid.rStudy

▶ Macrolides (erythromycin) moderately increase the exposure to

eletriptan. Avoid.oStudy

▶ Netupitant

o

is predicted to increase the exposure to eletriptan.

Study

Eliglustat

▶ Abiraterone is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Eliglustat is predicted to increase the exposure to aliskiren.

Adjust dose.oStudy

▶ Antiarrhythmics (dronedarone, propafenone) are predicted to

increase the exposure to eliglustat. Avoid or adjust dose—

consult product literature.rStudy

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the exposure

to eliglustat. Avoid.rStudy

▶ Antifungals, azoles (fluconazole, isavuconazole, itraconazole,

ketoconazole, posaconazole, voriconazole) are predicted to

increase the exposure to eliglustat. Avoid or adjust dose—

consult product literature.rStudy

▶ Eliglustat is predicted to increase the exposure to

antihistamines, non-sedating

o

(fexofenadine). Adjust dose.

Study

▶ Aprepitant is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Eliglustat is predicted to increase the exposure to atomoxetine.

Adjust dose.oTheoretical

▶ Eliglustat is predicted to increase the exposure to beta blockers,

non-selective (propranolol). Adjust dose.oStudy

▶ Eliglustat is predicted to increase the exposure to beta blockers,

selective (metoprolol). Adjust dose.oStudy

▶ Bosentan

o

is predicted to decrease the exposure to eliglustat.

Theoretical

▶ Bupropion is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the exposure to eliglustat. Avoid or adjust dose—

consult product literature.rStudy

▶ Cinacalcet is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Cobicistat is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Eliglustat is predicted to increase the exposure to colchicine.

Avoid or adjust colchicine dose, p. 1120.rTheoretical

▶ Crizotinib is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

1448 Efavirenz — Eliglustat BNF 78

Interactions | Appendix 1

A1

▶ Eliglustat is predicted to increase the exposure to dabigatran.

Adjust dose.oStudy

▶ Eliglustat

o

increases the exposure to digoxin. Adjust dose.

Study

▶ Duloxetine is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Eliglustat is predicted to increase the exposure to edoxaban.

Adjust dose.oStudy

▶ Efavirenz

o

is predicted to decrease the exposure to eliglustat.

Theoretical

▶ Enzalutamide is predicted to decrease the exposure to

eliglustat. Avoid.rStudy

▶ Eliglustat is predicted to increase the exposure to everolimus.

Adjust dose.oStudy

▶ Grapefruit juice is predicted to increase the exposure to

eliglustat. Avoid.rTheoretical

▶ HIV-protease inhibitors are predicted to increase the exposure

to

r

eliglustat. Avoid or adjust dose—consult product literature.

Study

▶ Idelalisib is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Imatinib is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Eliglustat is predicted to increase the exposure to loperamide.

Adjust dose.oStudy

▶ Macrolides (clarithromycin, erythromycin) are predicted to

increase the exposure to eliglustat. Avoid or adjust dose—

consult product literature.rStudy

▶ Mirabegron is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Mitotane is predicted to decrease the exposure to eliglustat.

Avoid.rStudy

▶ Moclobemide is predicted to increase the exposure to

eliglustat

r

. Avoid or adjust dose—consult product literature.

Theoretical

▶ Netupitant is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Nevirapine

o

is predicted to decrease the exposure to eliglustat.

Theoretical

▶ Nilotinib is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Quinolones (ciprofloxacin) are predicted to increase the

exposure to eliglustat. Avoid or adjust dose—consult product

literature.rTheoretical

▶ Rifampicin is predicted to decrease the exposure to eliglustat.

Avoid.rStudy

▶ Eliglustat is predicted to increase the exposure to sirolimus.

Adjust dose.oStudy

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to eliglustat. Avoid or adjust dose—consult product

literature.rStudy

▶ St John’s Wort is predicted to increase the exposure to

eliglustat. Avoid.rStudy

▶ Eliglustat is predicted to increase the exposure to taxanes

(paclitaxel). Adjust dose.oStudy

▶ Terbinafine is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Eliglustat is predicted to increase the exposure to tolterodine.

Adjust dose.oTheoretical

▶ Eliglustat is predicted to increase the exposure to topotecan.

Adjust dose.oStudy

▶ Eliglustat is predicted to increase the exposure to tricyclic

antidepressants (nortriptyline). Adjust dose.oTheoretical

Elotuzumab → see monoclonal antibodies

Eltrombopag

▶ Antacids decrease the absorption of eltrombopag. Eltrombopag

should be taken 2 hours before or 4 hours after

r

antacids.

Study

▶ Oral calcium salts decrease the absorption of eltrombopag.

Eltrombopag should be taken 2 hours before or 4 hours after

calcium salts.rStudy

▶ Ciclosporin decreases the exposure to eltrombopag. Monitor

and adjust dose.oStudy

▶ Dairy products are predicted to decrease the absorption of

eltrombopag. Eltrombopag should be taken 2 hours before or

4 hours after dairy products.rTheoretical

▶ Iron (oral) is predicted to decrease the absorption of

eltrombopag. Eltrombopag should be taken 2 hours before or

4 hours after iron (oral).rTheoretical

▶ Eltrombopag is predicted to increase the concentration of

letermovir.oStudy

▶ Eltrombopag is predicted to increase the concentration of

methotrexate.oTheoretical

▶ Rifampicin is predicted to decrease the exposure to

eltrombopag and eltrombopag is predicted to increase the

concentration of rifampicin.oTheoretical

▶ Oral selenium is predicted to decrease the absorption of

eltrombopag. Eltrombopag should be taken 2 hours before or

4 hours after selenium.rTheoretical

▶ SSRIs (fluvoxamine) are predicted to increase the exposure to

eltrombopag.oTheoretical

▶ Eltrombopag is predicted to increase the exposure to statins.

Monitor and adjust dose.oStudy

▶ Eltrombopag is predicted to increase the exposure to tenofovir

alafenamide.oTheoretical

▶ Eltrombopag is predicted to increase the exposure to tenofovir

disoproxil.oTheoretical

▶ Oral zinc is predicted to decrease the absorption of

eltrombopag. Eltrombopag should be taken 2 hours before or

4 hours after zinc.rTheoretical

Elvitegravir

▶ Antacids moderately decrease the exposure to elvitegravir.

Separate administration by at least 4 hours.oStudy

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the

concentration of elvitegravir. Avoid.rTheoretical

▶ Bosentan is predicted to decrease the concentration of

elvitegravir. Avoid.rTheoretical

▶ Elvitegravir is predicted to decrease the anticoagulant effect of

coumarins.oTheoretical

▶ Efavirenz is predicted to decrease the concentration of

elvitegravir. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the concentration of

elvitegravir. Avoid.rTheoretical

▶ Elvitegravir markedly increases the exposure to grazoprevir.

Avoid.rStudy

▶ HIV-protease inhibitors (atazanavir, lopinavir) (boosted with

ritonavir) increase the concentration of elvitegravir. Refer to

specialist literature.oStudy

▶ Mitotane is predicted to decrease the concentration of

elvitegravir. Avoid.rTheoretical

▶ Nevirapine is predicted to decrease the concentration of

elvitegravir. Avoid.rTheoretical

▶ Rifampicin is predicted to decrease the concentration of

elvitegravir. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the concentration of

elvitegravir. Avoid.rTheoretical

Empagliflozin → see TABLE 14 p. 1378 (antidiabetic drugs), TABLE 8

p. 1376 (hypotension)

Enalapril → see ACE inhibitors

Encorafenib → see TABLE 9 p. 1377 (QT-interval prolongation)

▶ Antiarrhythmics (dronedarone) are predicted to moderately

increase the exposure to encorafenib.oStudy → Also see

TABLE 9 p. 1377

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the exposure

to encorafenib.rTheoretical

▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)

are predicted to moderately increase the exposure to

encorafenib.oStudy → Also see TABLE 9 p. 1377

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the exposure to encorafenib. Avoid or

monitor.rStudy → Also see TABLE 9 p. 1377

▶ Aprepitant is predicted to moderately increase the exposure to

encorafenib.oStudy

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

moderately increase the exposure to

Study

encorafenib.o

BNF 78 Eliglustat — Encorafenib 1449

Interactions | Appendix 1

A1

Encorafenib (continued)

▶ Cobicistat is predicted to increase the exposure to encorafenib.

Avoid or monitor.rStudy

▶ Encorafenib is predicted to affect the exposure to combined

hormonal contraceptives.rTheoretical

▶ Crizotinib is predicted to moderately increase the exposure to

encorafenib.oStudy → Also see TABLE 9 p. 1377

▶ Encorafenib is predicted to increase the exposure to

dolutegravir.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

encorafenib.rTheoretical

▶ Grapefruit juice is predicted to increase the exposure to

encorafenib. Avoid.oStudy

▶ HIV-protease inhibitors are predicted to increase the exposure

to encorafenib. Avoid or monitor.rStudy → Also see

TABLE 9 p. 1377

▶ Idelalisib is predicted to increase the exposure to encorafenib.

Avoid or monitor.rStudy

▶ Imatinib is predicted to moderately increase the exposure to

encorafenib.oStudy

▶ Macrolides (clarithromycin) are predicted to increase the

exposure to encorafenib. Avoid or monitor.rStudy → Also

see TABLE 9 p. 1377

▶ Macrolides (erythromycin) are predicted to moderately increase

the exposure to encorafenib.oStudy → Also see TABLE 9

p. 1377

▶ Mitotane

r

is predicted to decrease the exposure to encorafenib.

Theoretical

▶ Netupitant is predicted to moderately increase the exposure to

encorafenib.oStudy

▶ Nilotinib is predicted to moderately increase the exposure to

encorafenib.oStudy → Also see TABLE 9 p. 1377

▶ Encorafenib is predicted to increase the exposure to

raltegravir.oTheoretical

▶ Rifampicin is predicted to decrease the exposure to

encorafenib.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

encorafenib.rTheoretical

Enoxaparin → see low molecular-weight heparins

Entacapone

▶ Iron (oral) is predicted to decrease the absorption of

entacapone

o

. Separate administration by at least 2 hours.

Theoretical

▶ Entacapone increases the exposure to levodopa. Monitor side

effects and adjust dose.oStudy

▶ Entacapone is predicted to increase the exposure to

methyldopa.oTheoretical

▶ Entacapone is predicted to increase the risk of elevated blood

pressure when given with monoamine-oxidase A and B

inhibitors, irreversible. Avoid.rTheoretical

▶ Entacapone is predicted to increase the risk of cardiovascular

o

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more